The British newspaper “The Telegraph” quoted the pharmaceutical company AstraZeneca that the injection of cloned antibodies that fight the Covid 19 epidemic proved very effective in those with early-stage infection.
Pascal Suryot, CEO of British Swedish Pharmaceutical Company, told the newspaper that the treatment being developed is a “mixture of two antibodies” in a single dose because “this works to reduce the resistance of the virus if the injection contains one antibody.”
Suryot added that antibody therapy is more expensive than the vaccine, noting that the priority in providing treatment will be for the elderly and vulnerable who do not have the ability to develop a good response to the vaccine.
And AstraZeneca signed last Thursday an agreement with the “Epidemiological Innovation Alliance,” CEPI, to help manufacture 300 million doses of the vaccine against the Corona virus, which is being developed by the Jenner Institute at Oxford University.
According to the newspaper, AstraZeneca has already begun making a vaccine against “Covid 19” at Oxford University in the hope of its success, passing human experiences and availability in the market this fall.
According to The Telegraph, experiments with a possible vaccine have begun in Brazil, which has become a new epidemic center, to ensure that the study can be properly tested with lower transmission rates in the UK.
The Jenner Institute and the Oxford vaccine group began developing a vaccine in January, using a virus from chimpanzees.
The Institute of Sera in India, which is a member of the Epidemiological Innovation Alliance, is building other “parallel” partnerships with AstraZeneca to fund antibody treatment as an independent treatment for the virus.
Meanwhile, the UK-based vaccine maker Seqirus, a vaccine company, has partnered with its parent company, CSL, and Seppy Alliance and the University of Queensland in Australia to help develop a vaccine against the Covid 19 epidemic in Australia.
The manufacturing center, based in the English city of Liverpool, produces supportive treatments similar to those given to cancer patients, with the aim of improving the immune response to the vaccine.